OTCM
CORBF
Market cap127mUSD
Oct 08, Last price
0.95USD
1D
0.00%
1Q
0.11%
Jan 2017
-84.46%
IPO
-83.46%
Name
Global Cord Blood Corp
Chart & performance
P/E
—
P/S
—
EPS
3.74
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
11.52%
Revenues
1.24b
+7.21%
Net income
501m
-1.41%
CFO
614m
-2.71%
Dividend
Jul 27, 20180.08 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Global Cord Blood Corporation, headquartered in Central, Hong Kong, primarily offers umbilical cord blood preservation and related support services within the People's Republic of China. The company's operations include the comprehensive testing, processing, and long-term storage of cord blood samples for its individual clients. Additionally, it undertakes the examination, preparation, and storage of donated cord blood units, facilitating their use for matching purposes. As of March 31, 2022, the corporation oversaw the management of three distinct cord blood banks, located in Beijing municipality, Guangdong province, and Zhejiang province. The entity previously operated as China Cord Blood Corporation, adopting its current name in March 2018, and functions as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Key people
Ting Zheng
Chairman of the Board, Chief Executive Officer and Chief Executive Officer - Beijing Division · since 2018
Rui Arashiyama
Chief Executive Officer - Guangdong and Zhejiang Divisions
Xin Xu
Chief Technology Officer
Albert Chen
Chief Financial Officer, Director
Ping Xu
Non-Executive Director · since 2018
Mark Chen
Independent Non-Executive Director
Siu Chuen Cheng
Independent Non-Executive Director · since 2020
Jack Chow
Independent Non-Executive Director · since 2019
Ken Lu
Independent Non-Executive Director · since 2009
Jennifer Weng
Independent Non-Executive Director
IPO date
Nov 19, 2009
Employees
Domiciled in
HK
Incorporated in
KY
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT |